Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

Basit Öğe Kaydı
dc.authorscopusid7006046625
dc.authorscopusid55987915300
dc.authorscopusid56891371400
dc.authorscopusid57205580317
dc.authorscopusid57193238894
dc.authorscopusid54980627800
dc.authorscopusid57222142906
dc.contributor.authorErdogan B.
dc.contributor.authorKostek O.
dc.contributor.authorHacioglu M.B.
dc.contributor.authorGokyer A.
dc.contributor.authorKucukarda A.
dc.contributor.authorOzcan E.
dc.contributor.authorGokmen I.
dc.date.accessioned2024-06-12T10:28:26Z
dc.date.available2024-06-12T10:28:26Z
dc.date.issued2021
dc.description.abstractPurpose: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma. Methods: Forty-one patients with metastatic clear cell renal carcinoma (mRCC) (n=22) and advanced stage soft tissue sarcoma (STS) (n=19) were assessed. Systemic inflammatory markers such as neutrophils, lymphocytes, c-reactive protein (CRP), mean platelet volume (MPV), lactate dehydrogenase (LDH) and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at both baseline and 1-month of pazopanib treatment were obtained and their relation with the first radiological response about 3-months later after pazopanib treatment was evaluated. Results: Disease control rate (DCR) at the first initial radiological evaluation was 58.5 % for all, it was 77.3% for the RCC group and 36.8% in the STS group. Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed. Conclusions: Early decline in serum CRP, neutrophil and NLR levels in RCC patients who received pazopanib at the first month was significantly associated with disease control, assuming a predictive role for the first radiological assessment. However, there was no significant association between change in serum inflammatory marker levels and disease control in STS patients. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage2201en_US
dc.identifier.issn1107-0625
dc.identifier.issue5en_US
dc.identifier.pmid34761635en_US
dc.identifier.scopus2-s2.0-85118790734en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2196en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17252
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDisease Control; Inflammatory Markers; Metastatic Renal Cell Carcinoma; Pazopanib; Soft Tissue Sarcomaen_US
dc.subjectBiological Marker; C Reactive Protein; Interferon; Lactate Dehydrogenase; Pazopanib; Biological Marker; Indazole Derivative; Pazopanib; Pyrimidine Derivative; Sulfonamide; Adult; Aged; Cancer Control; Cancer Patient; Cancer Staging; Clear Cell Renal Cell Carcinoma; Clinical Article; Clinical Assessment; Comparative Effectiveness; Controlled Study; Drug Efficacy; Female; Human; Inflammation; Kidney Metastasis; Lymphocyte Count; Male; Mean Platelet Volume; Neutrophil Count; Neutrophil Lymphocyte Ratio; Platelet Lymphocyte Ratio; Radiography; Renal Cell Carcinoma; Retrospective Study; Review; Soft Tissue Sarcoma; Treatment Outcome; Treatment Response; Blood; Complication; Inflammation; Kidney Tumor; Middle Aged; Pathology; Sarcoma; Soft Tissue Tumor; Time Factor; Aged; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Indazoles; Inflammation; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Time Factors; Treatment Outcomeen_US
dc.titleIs early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu